Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Multicenter Study to Assess the Safety and Efficacy of Topical Zabalafin Hydrogel Versus Vehicle in the Treatment of Participants With Mild to Moderate Atopic Dermatitis (CLEAR-AD1)

NCT06855745 is registered in ClinicalTrials.gov with Alphyn Biologics as lead sponsor.

NCT NCT06855745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06855745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Multicenter Study to Assess the Safety and Efficacy of Topical Zabalafin Hydrogel Versus Vehicle in the Treatment of Participants With Mild to Moderate Atopic Dermatitis (CLEAR-AD1)
Lead sponsor
Alphyn Biologics
Phase
Phase 2
Overall status
Recruiting
Start date
March 25, 2025
Completion date
November 28, 2025
Enrollment
72 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis, atopic dermatitis (ad), atopic dermatitis (eczema), atopic dermatitis eczema, eczema, eczema, atopic